Mirvetuximab Soravtansine治療鉑抗藥性卵巢癌的檢視

The role of mirvetuximab soravtansine for the treatment of platinumresisitant ovarian cancer

抗體藥物複合體乃由化學性斷裂或不斷裂鍊接器，將人類抗體與毒物藥物結合後，然後釋放至含標靶的腫瘤細胞中將其消滅。2022年，美國食品藥物管理局（FDA）通過可用mirvetuximab soravtansine（MIRV）來治療經1-3線化學治療後、含陽性葉酸受體α（FRα）、鉑抗藥性的上皮性卵巢癌、輸卵管癌和原發性腹膜癌。唯MIRV嚴重副作用有眼睛病變、末梢神經病變和肺炎等，或需考慮劑量減少，暫時或永久停用。

The antibody-drug conjugates (ADCs), formed by a humanized antibody and a small drug via a chemical cleavable or non-cleavable linker, have emerged as a potential treatment strategy in cancer disease. In November 2022, the Food and Drug Administration (FDA) approved mirvetuximab soravtansine (MIRV) for adult patients with folate receptor alpha (FRα) positive, platinumresistant epithelial ovarian, follopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Howevew, the severe adverse events of MIRV induding ocular events, peripheral neuropathy and pneumonitis, therefore, dose reduction, dose interruptions and permanent treatment discontinuation needed to consideration.